The clinical application of immune checkpoint therapies (ICTs), including anti-PD1/PD-L1 (PD1 ligand 1) antibody therapy, can restore T-cell immune function to a certain extent and increased the likelihood of tumour patient survival [22]. The gene discussed is CD274; the disease is neoplasm.